Education
About Us
Working with TipRanks
Follow Us
Corvus Pharmaceuticals Inc (CRVS)
NASDAQ:CRVS
CRVS Stock Chart & Stats
$7.49
-$0.10(-1.74%)
At close: 4:00 PM EST
$7.49
-$0.10(-1.74%)
Day’s Range― - ―
52-Week Range$2.54 - $9.60
Previous CloseN/A
Volume202.27K
Average Volume (3M)1.17M
Market Cap
$559.37M
Enterprise Value$545.83M
Total Cash (Recent Filing)$65.69M
Total Debt (Recent Filing)$1.01M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Mar 05, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding74,681,870
10 Day Avg. Volume1,786,598
30 Day Avg. Volume1,173,946
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)10.02
Price to Sales (P/S)0.00
P/FCF Ratio-12.83
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-14.23
Forecast
1Y Price Target
$13.33Price Target Upside77.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$620.00K
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMajor clinical readouts expected in the next 12 months, with three major clinical results anticipated in 2026.
Drug DevelopmentCorvus Pharmaceuticals is advancing its atopic dermatitis clinical program and is ready to move soquelitinib into a Phase 2 study following strong results.
Regulatory ApprovalsThe company's partner in China, Angel Pharmaceuticals, has received regulatory clearance to initiate a Phase 1/2 study in China, expanding the geographical scope of clinical testing.
Bears Say
Financial PerformanceThe company reported no revenues for the quarter, in-line with the consensus estimate.
Corvus Pharmaceuticals News
CRVS FAQ
What was Corvus Pharmaceuticals Inc’s price range in the past 12 months?
Corvus Pharmaceuticals Inc lowest stock price was $2.54 and its highest was $9.60 in the past 12 months.
What is Corvus Pharmaceuticals Inc’s market cap?
Corvus Pharmaceuticals Inc’s market cap is $559.37M.
When is Corvus Pharmaceuticals Inc’s upcoming earnings report date?
Corvus Pharmaceuticals Inc’s upcoming earnings report date is Mar 05, 2026 which is in 74 days.
How were Corvus Pharmaceuticals Inc’s earnings last quarter?
Corvus Pharmaceuticals Inc released its earnings results on Nov 04, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.127 by $0.007.
Is Corvus Pharmaceuticals Inc overvalued?
According to Wall Street analysts Corvus Pharmaceuticals Inc’s price is currently Undervalued.
Does Corvus Pharmaceuticals Inc pay dividends?
Corvus Pharmaceuticals Inc does not currently pay dividends.
What is Corvus Pharmaceuticals Inc’s EPS estimate?
Corvus Pharmaceuticals Inc’s EPS estimate is -0.13.
How many shares outstanding does Corvus Pharmaceuticals Inc have?
Corvus Pharmaceuticals Inc has 74,681,870 shares outstanding.
What happened to Corvus Pharmaceuticals Inc’s price movement after its last earnings report?
Corvus Pharmaceuticals Inc reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.127. Following the earnings report the stock price went down -1.44%.
Which hedge fund is a major shareholder of Corvus Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in CRVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corvus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.33 (77.97% Upside)
$13.33 (77.97% Upside)
Blogger Sentiment
Bullish
CRVS Sentiment 75%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.15%
12-Months-Change
Fundamentals
Return on Equity
-35.82%
Trailing 12-Months
Asset Growth
36.83%
Trailing 12-Months
Company Description
Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals (CRVS) is a biotechnology company focused on the development and commercialization of innovative immuno-oncology therapies. The company is engaged in the research and development of novel drugs designed to harness the immune system to treat cancer. Corvus Pharmaceuticals' core product pipeline includes small molecule and antibody therapies targeting various immune checkpoints and pathways crucial for cancer treatment.
CRVS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented significant positive developments, including a notable reduction in net loss, a strong cash position, and successful clinical trial progress for soquelitinib. However, increased R&D expenses and delays in trial result reporting were challenges. Overall, the positive aspects, particularly related to clinical advancements and financial improvements, seem to outweigh the negatives.View all CRVS earnings summariesCRVS Stock 12 Month Forecast
Average Price Target
$13.33
▲(77.97% Upside)
Technical Analysis
Ownership Overview
22.92% Insiders
6.42% Mutual Funds
26.77% Other Institutional Investors
35.53% Public Companies and
Individual Investors